Brigham Young University

BYU ScholarsArchive
Theses and Dissertations
2022-08-11

Big Data Meta-Analyses of Transcriptional Responses of Human
Samples to Orthohantavirus Infection and Shotgun
Metagenomics From Crohn's Disease Patients.
John L. Krapohl
Brigham Young University

Follow this and additional works at: https://scholarsarchive.byu.edu/etd
Part of the Life Sciences Commons

BYU ScholarsArchive Citation
Krapohl, John L., "Big Data Meta-Analyses of Transcriptional Responses of Human Samples to
Orthohantavirus Infection and Shotgun Metagenomics From Crohn's Disease Patients." (2022). Theses
and Dissertations. 9667.
https://scholarsarchive.byu.edu/etd/9667

This Thesis is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion
in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please
contact ellen_amatangelo@byu.edu.

Big Data Meta-Analyses of Transcriptional Responses of Human Samples to Orthohantavirus Infection
and Shotgun Metagenomics from Crohn’s Disease Patients

John L. Krapohl

A thesis submitted to the faculty of
Brigham Young University
in partial fulfillment of the requirements for the degree of
Master of Science

Brett E. Pickett, Chair
K. Scott Weber
Bradford K. Berges

Department of Microbiology and Molecular Biology
Brigham Young University

Copyright © 2022 John L. Krapohl
All Rights Reserved

ABSTRACT
Big Data Meta-Analyses of Transcriptional Responses of Human Samples to Orthohantavirus Infection
and Shotgun Metagenomics from Crohn’s Disease Patients
John L. Krapohl
Department of Microbiology and Molecular Biology, BYU
Master of Science
Hantavirus is a dangerous zoonotic viral pathogen that is found across Asia, Europe, and the
Americas. This virus causes a range of symptoms from flu-like malaise to heart failure and death. It is
normally transmitted to humans via the aerosolized feces or urine of infected rodents. Currently, there are
no known treatments for the disease, and it continues to threaten human health in endemic areas. In order
to identify possible future therapeutic targets, we ran a meta-analysis of existing transcriptomic data
collected from infected human tissue. Several genes and cellular pathways were identified, in addition to
several potential therapeutics that warrant additional testing as potential future therapeutics for hantavirus
infection. Such genes include, but are not limited to SLC27A3, NOG, AMIGO1, NUSAP1, and CDC25C
which have not been previously associated with hantavirus infection. In addition, we identified that RIG-I
and MDA5-associated anti-viral response genes are downregulated, while downstream elements of these
pathways are upregulated, indicative of immune activation via alternate pathways. Finally, among the
potential therapeutics we identified are dinaciclib, alvodicib, and ruxolitinib, which limit cellular
replication, as well as ruxolitinib, baricitinib, and tofacitinib, which target other human intracellular
pathways that may aid in successful viral infection.
Crohn’s disease is an autoimmune disorder that affects the digestive system of more than six
million people worldwide, with most cases found in North America and Europe. Although the disease can
occur throughout the entire digestive tract, the classical sign of disease progression is inflammation of the
intestine. There are a number of factors that have been associated with the onset and progression of the
disease including diet, antibiotics, stress, and bacterial infections, but no putative cause has been found.
As diet and the gut biome play a significant role in disease progression, we aimed to find commonalities
in the gut microbiomes of Crohn’s patients, even when located in different geographical areas.
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INTRODUCTION
Hantavirus and Health Outcomes
Orthohantavirus is a genus that belongs to the family Hantaviridae in the order Bunyavirales,
meaning it has a three-segment negative-sense RNA genome[1]. While the genome is linear, each segment
can form a panhandle structure through complementary base pairing of the 5’ and 3’ ends, which is then
bound by the viral RdRP (RNA-dependent RNA polymerase) and nucleocapsid protein[2]. The entirety of
each genomic segment is bound by nucleocapsid protein forming three unique nucleocapsid
macromolecules in each virion[3]. The large (L) segment codes for the RdRP. The medium (M) segment
encodes a glycoprotein precursor that is cleaved into the Gn and Gc subunits prior to dimerization into the
functional glycoprotein[3]. The small (S) segment encodes the nucleocapsid (N) protein that binds to the
viral nucleic acid. Some hantavirus species have been shown to have a functional nonstructural protein
encoded on the reverse strand of the S segment as well, but it is largely uncharacterized. The main entry
receptor for hantaviruses is the host b3- integrin, which transports the virus into the cell through cellular
endocytosis[2](Figure 1-1). In addition, hantaviruses belonging to the new world clade rely on
protocadherin-1, and old-world hantaviruses rely on CD55 as an entry receptor [4, 5].
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Figure 1-1: Overview of Hantavirus Replication in Host Cell. After hantavirus binds to integrin beta, it
is endocytosed. After entry, hantavirus replicates its genome and creates viral components, packages
itself, and escapes the cell[1, 2]. Note: Some new world hantaviruses assemble at the cellular
membrane[1].

The first member of the viral family Hantaviridae was originally isolated in 1978 by Dr. Ho Wang
Lee during his search for the cause of an outbreak of Korean hemorrhagic fever. The causative agent was
subsequently named the Hantaan virus, due to the outbreak’s proximity to the Hantaan river[6]. Within
this viral family is the genus Orthohantavirus, which consists of viruses that are endemic within rodent
populations and are commonly referred to as hantaviruses. These viruses do not cause disease within their
rodent host; rather, they are able to maintain a persistent infection without becoming pathogenic or
symptomatic[7]. However, as human populations and cities have expanded, there has been increasing
contact with rodent species resulting in viral spillover and increased human infection[8]. Depending on
2

weather patterns, rodent populations may rapidly increase, resulting in a greater risk of hantavirus spread.
This phenomenon generally causes hantavirus epidemics every few years throughout Asia and Europe.
However, despite the ever-present risk of disease, with cases reaching over 10,000 in China
annually, no treatment has been shown to be completely effective in treating hantavirus infection, especially
once viremia occurs[9]. One of the primary reasons for this lack of therapeutic options is that the virus has
a 2-6 week incubation time between infection and symptoms, at which point infection is already well
established and difficult to treat[10]. While tracing and identifying the initial infection is difficult,
hantavirus infection is not transmitted human-to-human, but solely by exposure to rodents and rodent
droppings[11].
Hantavirus infection in humans is known to cause two manifestations of disease: Hantavirus
Cardiopulmonary Syndrome (HCPS) and Hemorrhagic Fever with Renal Syndrome (HFRS). Old-world
hantaviruses, being those found natively in Asia and Europe, are responsible for HFRS, while new-world
hantaviruses are responsible for HCPS. HFRS causes flu-like aches and fever, often followed by shock
and renal failure which can lead to death[2]. Depending on the viral species, mortality can occur in 1-12%
of cases(12). However, HCPS is much more deadly, due to the loss of barrier integrity in the heart and
lung endothelium, causing death in about 40% of cases[12].
Hantaviruses target human endothelial tissue by binding to integrin beta-3, which is found in high
quantities on most human endothelial cells[13] (Figure 1-1). When a human cell is infected, hantaviruses
replicate without causing cytopathic effects or apoptosis[14]. Instead, host immune cells are recruited and
attack the tissue, causing intercellular junctions to break down. This causes edema in the tissue and the
symptoms of hantaviral disease[15]. It is widely accepted that a cytokine storm results in excessive Tlymphocyte activity, which is the etiological factor that drives HCPS and HFRS; however, recent studies
have shown that other immune cells, such as neutrophils and dendritic cells, may play an important role in
pathogenesis[16-18]. Interestingly, both old and new world hantaviruses are capable of infecting and
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replicating in a broad range of tissues[13]. However, old world hantavirus infections typically only result
in disease in the kidneys, and new world infections usually only result in disease in the lungs and heart.
While there are some reported instances of hantavirus pathogenesis in other organs, the defining feature
of HFRS and HCPS is disease in their respective primary target organ[13]. Researchers have not yet been
able to determine the underlying molecular mechanisms that influence tissue-specific pathogenesis for
hantaviruses. Part of this thesis work was to perform a meta-analysis of all publicly-available RNA-seq
data of hantavirus infected tissue to identify genes and signaling pathways that previously have not been
identified but may play a role in of host-based mechanisms of hantavirus pathogenesis. Chapter 2 will
show how this methodology was used to determine underlying genes and cellular pathways associated
with hantavirus infection both within primary cells and cultured cell lines.

Crohn’s Disease and Metagenomics
Crohn’s disease (CD) affects millions of people of worldwide, especially in developed
countries[19]. Over 3 million people in the US have been diagnosed with this disease, and over the past
30 years, incidence rates of CD in the US are increasing[19, 20]. This has been attributed to unhealthy
diet and increased use of antibiotics along with better sanitation[21, 22]. While there is no widelyaccepted singular cause of disease incidence or progression of the disease, bacterial dysbiosis, as well as
small intestinal bacterial overgrowth (SIBO), have been associated with severe disease[23-25]. Several
bacteria including Mycobacterium paratuberculosis and Helicobacter pylori have been suggested in the
past as possible causes; however, while the treatment of these pathogens can alleviate symptoms, it
cannot be described as a cure[26-28].
Although patients with CD can be found around the world, most patients are of European
descent[29, 30]. However, this observation is changing as incidence rates in Asian countries are steadily
climbing[31, 32]. Given this shift and the increasing amount of publicly available data from studies
performed in human patients in these countries, we have the opportunity to analyze CD at a more global
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scale and to identify any underlying commonalities between different populations of CD patients. We
used multiple shotgun metagenomic datasets of the gut microbiome collected from case and control
patients in the United States to better characterize the patterns that were consistently observed among
each group of patients.
This project used data from shotgun metagenomic sequencing data rather than using ampliconbased 16S sequencing. In 16S amplicon sequencing, after the DNA is extracted from the community of
microbes, the 16S ribosomal RNA gene is isolated and amplified through PCR. Because this gene is
highly conserved between different bacterial and archaeal species within a genus, this allows researchers
to identify and quantify bacterial diversity within a population with relatively little sequencing needed.
This is much cheaper and bioinformatically straightforward than normal sequencing and requires fewer
sequencing reads to achieve excellent sequencing depth. The drawback to this approach is the inability to
determine any additional qualities or attributes of any individual species. In addition, since only known
16S sequences are matched against a database of reference sequences, any novel microbe remains
unidentified.
With shotgun metagenomic sequencing, the DNA from the community of microbes is processed
and sequenced together without selecting for any particular locus. This generates substantially larger
datasets and consequently requires much more time- and computationally-intensive bioinformatic
processing to process, analyze, and interpret the data. The increased resources associated with this
approach are required to obtain sufficiently high sequencing depth and to ensure adequate coverage of the
sample. A shotgun metagenomics approach can identify both genes and novel species and can give insight
into microbial interactions within a biological system. Thus, shotgun metagenomics can have a greater
impact in healthcare settings when trying to understand the microbiome of human systems and the
underlying mechanism(s) of infection and disease.

5

After sequencing data from a shotgun metagenomics sample is collected and processed for
quality control, it must go through an assembly workflow. If normal read assembly is compared to
assembling a puzzle, metagenomic read assembly would be like assembling puzzles from several hundred
puzzles where all the pieces are mixed together. Naturally, this is computationally expensive, and only
somewhat recently has the required computational capacity become sufficient to make this problem
tractable. Reads are assembled into contigs, and then passed to a step known as binning. Contigs are
grouped together based on relative abundance and other biological features such as GC content. Contigs
grouped together into a bin are considered to be a draft genome of a single species. From there the contigs
can be reassembled into a viable genome. A genome is considered good enough to work with and
representative of a real organism if the bin is calculated to be at least 70 percent complete with less than 5
percent contamination. Chapter 3 uses this binning technique to identify species within our samples and
identify potentially harmful genes within those bins to determine if there are significant differences in the
gut biome between those with Crohn’s in the US and the controls. Chapter 4 is a description of code I
wrote used to simplify and automate the necessary processes to create and characterize those bins.

CHAPTER 2
META-ANALYSIS OF TRANSCRIPTOMIC DATASETS QUANTIFIES DIFFERENTIAL GENE
EXPRESSION, AFFECTED PATHWAYS, AND PREDICTED DRUGS FROM HANTAVIRUSINFECTED HUMAN MATERIAL
Taken from “Meta-Analysis of Transcriptomic Datasets Quantifies Differential Gene Expression,
Affected Pathways, and Predicted Drugs from Hantavirus-Infected Human Material”. Manuscript
currently in submission at Virology Journal, and on the Research Square preprint server
(https://assets.researchsquare.com/files/rs-1766515/v1/d8aeefef-4ac2-42df-b66ec77d5ad96f45.pdf?c=1656689339).
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ABSTRACT
We performed a meta-analysis that consisted of re-analyzing publicly available RNA-sequencing
datasets across representative species within Orthohantavirus and across host cell types to identify
differentially expressed genes associated with hantavirus infection. In addition, we determined signaling
pathways that were significantly perturbed in human tissue, as well as predicted existing drugs that could
be repurposed to potentially reduce the effects of acute hantavirus infection. The National Center for
Biotechnology Information Gene Expression Omnibus (NCBI-GEO) and European Nucleotide Archive
(ENA) databases were searched to find datasets for this analysis, then processed using the Automated
Reproducible Modular Workflow for Preprocessing and Differential Analysis of RNA-seq Data
(ARMOR) to identify differentially expressed genes (DEGs). The results from this analysis were then
processed using signaling pathway impact analysis (SPIA) to identify enriched signaling pathways.
Finally, those data were processed using the Pathways2Targets program to identify existing therapeutics
that target the impacted cellular pathways. Our results include affirming the roles of the previously
identified interferon pathway and the MYBL1 and CCR7 genes, as well as newly identified genes,
including SLC27A3, TSEN34 and neuron associated NOG and AMIGO1. We predicted dinaciclib,
alvodicib, and ruxolitinib, among many other drugs, that could be useful as potential HFRS and HCPS
treatments. These data can be used in the design of future wet lab experiments to better characterize the
human transcriptional response to infection, as well as to improve host-based diagnostics and/or
therapeutics to reduce the severity of hantavirus infection.

BACKGROUND
Orthohantavirus is a viral genus that includes the hantaviruses that are pathogenic in humans.
Members of this viral genus are transmitted by various rodent hosts throughout Asia, Europe, the
Americas, and parts of Africa [8]. These hantaviruses are generally well-adapted to their rodent host and
are unlikely to cause disease in that host. However, when humans come into direct contact with infected
rodent vectors or their feces, virions can enter host cells and potentially cause a productive infection [14].
7

Once human infection occurs, hantaviruses are far more likely to cause severe disease, permanent injury,
or even death. Human-to-human spread of hantaviruses generally does not occur, with the exception of
some rare cases of Andes virus [33]. However, as metropolitan areas continue to expand, the threat of
hantavirus spillover into humans is increasingly becoming a threat. This is especially true in eastern Asia,
where thousands of cases of hemorrhagic fever with renal syndrome (HFRS) due to hantavirus infection
are reported each year [8]. New world hantavirus disease, known as hantavirus cardiopulmonary
syndrome (HCPS), is far less common, but has been reported to have up to a 50% fatality rate [34]. It was
the new world hantavirus Sin Nombre virus that was responsible for the 1993 hantavirus outbreak in the
Four Corners region of the western United States [35].
Like all members of the Bunyavirales family, an Orthohantavirus virion is composed of a
segmented negative-sense RNA genome enclosed in a spherical capsid. Each of its three segments
encodes reading frames that code for the RNA-dependent RNA polymerase (RDRP), glycoprotein, and
the nucleocapsid (L, M, and S segments respectively) [1]. The glycoprotein precursor is cleaved by
endogenous proteases to form a heterodimeric protein receptor [3]. The integrin β3 surface protein serves
as the primary receptor for all infectious hantaviruses [36]. Past work has shown that hantaviruses do not
directly cause cytopathic effects in their host; rather that the host immune response to infection causes the
breakdown of endothelial integrity, leading to severe symptoms or death. To better understand the
pathogenesis of hantavirus, it is essential to characterize the underlying host intracellular transcriptional
responses. Currently, there are no FDA-approved treatments for hantavirus infection besides supportive
therapy, but effective vaccines are being investigated for several strains of hantavirus [37]. However,
vaccination may be difficult to administer due to the sporadic and relatively limited nature of many
hantavirus outbreaks.
Hantavirus infections are characterized by the loss of endothelial barrier integrity leading to
severe symptoms and death, as well as high levels of T-cell proliferation in affected tissue [38].
Interestingly, several prior experiments have shown that hantavirus infection causes no cytopathic effects
8

in vitro [3]. Instead, the highly elevated levels of cytokines along with T-cell levels in infected tissue
indicate that host inflammatory responses are primarily responsible for the observed clinical signs and
symptoms.
While several studies have examined the proteomics and health outcomes of infected individuals,
relatively little has been done to transcriptionally characterize human infection. Furthermore, no studies
have compared the host transcriptional response during hantavirus infection both in primary human
peripheral blood mononuclear cells (PBMC) and in human cell lines in vitro. Evidence of differentially
expressed genes (DEGs) across tissues would provide evidence that further research is required to
understand how these DEGs affect differences in morbidity in human tissues. This study seeks to further
examine how infection impacts host gene expression and intracellular signaling pathways by re-analyzing
existing human RNA-seq data collected during hantavirus infection. We anticipate that this approach will
enable us to better compare the DEGs across tissue types to predict more effective host-based
therapeutics.

METHODS
Data Acquisition
A search of the Gene Expression Omnibus (GEO) database, hosted at the National Center for
Biotechnology Information (NCBI; https://www.ncbi.nlm.nih.gov/geo/), was performed in mid-2021 to
find RNA-sequencing datasets for hantaviruses using terms including “hantavirus”, “Seoul virus”, “andes
virus”, “sin nombre virus” and “Hantaan virus”. In addition, these same terms were used to find relevant
datasets within the European Nucleotide Archive (ENA) database. The corresponding RNA-sequencing
data for five GEO series were retrieved from the Sequence Read Archive (SRA;
https://www.ncbi.nlm.nih.gov/sra) at NCBI: GSE158712, GSE161354, GSE133319, GSE133634,
GSE133751[39-41]. Sequencing data with the experiment accession number PRJEB41624 was also
downloaded from ENA and used in this analysis[42]. These datasets were generated from either human
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cell cultures (endothelial cell lines HUVEC or A549) infected with Hantaan Virus (HNTV) or Puumala
virus (PUUV) which are two similar viruses that are causative agents of HFRS, or peripheral blood
mononuclear cells (PBMC) harvested from patients who were infected with Hantaan Virus (HTNV) and
currently experiencing HFRS. The endothelial cell datasets and the primary PBMC datasets were
processed separately to generate data. The endothelial cell datasets will be referred to as the in vitro
analysis, while the PBMC datasets will be referred to as the primary PBMC analysis. The SRA files were
downloaded and converted to fastq format using GNU wget and version 2.10.1 of the NCBI sratools
software package (https://github.com/ncbi/sra-tools).

Data Processing
Much of the data processing was managed by the Automated Reproducible Modular Workflow
for Preprocessing and Differential Analysis of RNA-seq Data (ARMOR) [43]. Within this workflow the
data was processed as follows: quality control of the reads was performed using fastQC, adapters and
low-quality reads were trimmed using TrimGalore, reads were mapped and quantified to the GRCh38
human transcriptome using Salmon [44], and differential gene expression was calculated using edgeR
[45]. The list of DEGs from this workflow was subsequently analyzed with the Signaling Pathway Impact
Analysis (SPIA) algorithm [46], which uses pathway enrichment to identify cellular pathways using the
Biocarta, KEGG, NCI, Panther, and Reactome databases [47-50]. The SPIA output file from this analysis
was then analyzed with the Pathways2Targets program to identify existing therapeutics that target the
impacted cellular pathways [51] from the opentargets.org database [52]. The Search Tool for the Retrieval
of Interacting Genes/Proteins (STRING; https://string-db.org) database was used to identify and visualize
relevant protein-protein interactions [53].

RESULTS
We began by collecting the relevant fastq files for human-derived samples infected with
Orthohantavirus strains. In total, we included 73 samples from six datasets in this meta-analysis,
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including 23 controls, and included all pertinent data and metadata that could be extracted from the
NCBI-GEO and ENA databases [39-41]. Fastq files were divided into in vitro and primary PBMC groups
for the analysis according to sample type and each group was separately input to ARMOR. The primary
PBMC dataset consists of sequencing data from peripheral blood mononuclear cells (PBMC) of HFRS
(Hantaan virus infected) patients, with relevant control fastq files. The in vitro dataset consisted of A549
and HUVEC cells infected with either Hantaan or Puumala virus, with relevant control fastq files.
Primary PBMC Differentially Expressed Genes (DEGs)
We next used the automated ARMOR bioinformatics workflow to calculate genes with
significantly altered expression from the raw fastq files. We observed approximately 5900 significant
DEGs in the primary PBMC dataset (Figure 2-1), which consisted of human PBMC samples (corrected pvalue ≤ 0.05). This relatively high number of DEGs was expected since the infected material was being
affected by the host immune response. Interestingly, four of the most significant 50 genes have been
previously identified in earlier hantavirus studies including: OLFM1, CCR7, KLRG1, and PTGDR2—all
of which were downregulated [54-57]. We observed the most significant upregulated genes found were
NUSAP1, KIF20A, CDC25C, and DEPDC1.
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Figure 2-1: A Volcano Plot of Significance and Expression of DEGs in our Primary PBMC Analysis.
Genes with a log2 fold-change of less than |2| and/or an adjusted p-value < 0.05 are represented by
grey dots. Blue dots represent significantly downregulated genes, while red represent significantly
upregulated genes.
In Vitro Differentially Expressed Genes (DEGs)
We then wanted to perform a similar analysis on the in vitro dataset (cultured HUVEC and A549
infected cells). In this case, our analysis identified only 26 significant DEGs during infection including:
IFIT1, OAS2, CMPK2, IFIT3, IFI6. We found that three genes were downregulated, while the remaining
23 significant genes were upregulated (Figure 2-2).
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To better understand whether these gene products directly interacted with each other, we used the
STRING database to retrieve protein-protein interaction data [53]. We found that this protein network
revealed most of the proteins directly interact with each other, with two proteins not connected to the rest
of the graph and a third protein not represented in the database (Figure 2-3.)

Figure 2-2: A Volcano Plot of Significance and Expression of DEGs in the In Vitro Analysis of
Hantavirus Infection in Humans. Genes with a log2 fold-change of less than |2| and/or an adjusted p
value < 0.05 are represented by grey dots. Blue dots represent significantly downregulated genes,
while red represent significantly upregulated genes.
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Figure 2-3: A Protein-Protein Interaction Network of the Significant In Vitro Genes Generated from
the STRING Database. Known interactions (edges) connect proteins (nodes). (Not pictured:
AC090527.2 due to unknown function and interactions)

Pathway Analysis
After identifying the significant DEGs, we used them as input to the signaling pathway impact
analysis (SPIA) algorithm, which performs robust statistical analyses to identify cellular pathways that
were significantly enriched in DEGs [46]. We identified 79 enriched pathways in the primary PBMC
dataset, largely associated with transcription, cellular repair, homeostasis, and the cell cycle, with a few
associated with immune response (Table 2-1). In contrast, the in vitro dataset enrichment identified 11
pathways, all of which are associated with the antiviral response (Table 2-2).

Table 2-1: Top 10 Significantly Affected Signaling Pathways During Primary PBMC Human Hantavirus
Infection.
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Pathway Name

Status

Corrected p-value

Source
Database

Cytokine-cytokine receptor

Inhibited

4.96E-12

KEGG

Systemic lupus erythematosus

Activated

0.000115

KEGG

Cell cycle

Activated

0.000276

KEGG

Carbohydrate digestion and

Activated

0.000529

KEGG

Staphylococcus aureus infection

Activated

0.00062

KEGG

Alcoholism

Activated

0.006032

KEGG

Generic Transcription Pathway

Activated

7.52E-12

Reactome

interaction

absorption
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Activated PKN1 stimulates

Activated

5.01E-11

Reactome

Inhibited

5.01E-11

Reactome

Activated

5.26E-11

Reactome

transcription of AR (androgen
receptor) regulated genes KLK2 and
KLK3

RNA Polymerase I Promoter
Opening

Meiotic recombination

Table 2-2: All 11 Significantly Affected Signaling Pathways During In Vitro Human Hantavirus
Infection.

Pathway Name

Status

Corrected p-value

Source
Database

Influenza A

Activated

1.13E-08

KEGG

Herpes simplex infection

Activated

9.39E-06

KEGG

Measles

Activated

0.000117

KEGG

16

RIG-I-like receptor signaling

Activated

0.005427

KEGG

Interferon Signaling

Inhibited

3.68E-31

Reactome

Interferon alpha/beta signaling

Activated

1.21E-27

Reactome

Cytokine Signaling in Immune

Inhibited

8.60E-18

Reactome

Inhibited

5.06E-10

Reactome

ISG15 antiviral mechanism

Inhibited

5.06E-10

Reactome

Negative regulators of RIG-

Activated

5.49E-06

Reactome

Inhibited

7.24E-05

Reactome

pathway

system

Antiviral mechanism by IFNstimulated genes

I/MDA5 signaling

RIG-I/MDA5 mediated induction
of IFN-alpha/beta pathways

Potential Therapeutic Prediction
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We next wanted to predict existing drugs that could be repurposed as host-based therapies that
limit viral replication . We consequently used the enriched pathway data generated by SPIA as input to
the Pathways2Targets algorithm [51]. This software identifies known drug targets in the significant
pathways, then searches the public opentargets.org database to generate a list of potential therapeutics that
could affect each pathway. This method was justified since reversing the phenotype of the significantly
impacted pathways should reduce viral replication and/or pathogenesis. We sorted the results of this
analysis to prioritize therapeutics that were predicted to affect multiple pathways. We intentionally
selected this approach to maximize the potential effect of each drug by simultaneously interfering with
multiple intracellular processes that the virus uses to replicate. We generated predictions for the top 20
drugs for the primary PBMC and in vitro datasets (Table 2-3, Table 2-4). The top hits for the primary
PBMC analysis included dinaciclib, alvocidib, and roniciclib.
Table 2-3: Top 20 Therapeutics Predicted for the Primary PBMC Datasets Analyzed in This Study.

Predicted Therapeutic Name

Number of Target
Pathways

DINACICLIB

33

ALVOCIDIB

33

RONICICLIB

33

SELICICLIB

33

AT-7519

33

18

MILCICLIB

33

ATALUREN

33

ELX-02

33

MT-3724

33

UCN-01

24

PANOBINOSTAT LACTATE

23

ROMIDEPSIN

23

PANOBINOSTAT

23

BELINOSTAT

23

ENTINOSTAT

23

ABEXINOSTAT

23

VORINOSTAT

21

TACEDINALINE

19

AMG-232

17

19

APG115

17

Table 2-4: Top 20 Therapeutics Predicted for the In Vitro Datasets Analyzed in This Study.

Predicted Therapeutic Name

Number of Target
Pathways

RUXOLITINIB

7

BARICITINIB

7

RUXOLITINIB PHOSPHATE

7

TOFACITINIB

7

TOFACITINIB CITRATE

7

FILGOTINIB

7

UPADACITINIB

7

RONTALIZUMAB

6

SIFALIMUMAB

6

20

PF-06823859

6

PEGINTERFERON ALFA-2A

5

PEGINTERFERON ALFA-2B

5

INTERFERON BETA-1A

5

INTERFERON ALFA-2B

5

INTERFERON BETA-1B

5

INTERFERON ALFACON-1

5

ULIXERTINIB

5

LY3214996

5

RAVOXERTINIB

5

MK-8353

5

DISCUSSION
The purpose of this meta-analysis was to better characterize and compare the in vitro and primary
PBMC human intracellular transcriptional response to infection with various hantaviruses. Specifically,
we identified unique sets of DEGs in both comparisons that have been identified previously, as well as
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novel DEGs that could provide additional knowledge into the underlying mechanisms of viral
pathogenesis. We determined statistically significant signaling pathways that were enriched with the
identified DEGs for each set of samples, and subsequently used these pathways to predict potential
therapeutics that could be relevant to natural infections.
We believe that this analysis was somewhat hindered by the relatively small number of samples
in the public datasets. Specifically, the public data that we used came from HTNV-infected tissue, rather
than a variety of several hantaviruses. This is somewhat unsurprising due to various logistical reasons
including the difficulty and danger of culturing hantavirus in a laboratory setting, or a perceived lack of
interest in or access to hantavirus. Such studies can be quite useful in identifying potential causes or
compounding factors in HFRS and HCPS. Other hantaviruses, such as Andes virus and Sin nombre virus,
may cause far fewer infections each year, but infections by these pathogens have a higher mortality rate.
Much research is still needed to determine whether the differential expression patterns vary between
species of hantaviruses and between infected human tissue types, but this study attempts to address
hantaviruses as a whole in an attempt to identify common expression patterns between different viral
species. Our findings could potentially be applied across multiple hantaviruses.
We ran our data as two separate sets of data, differentiating between infected primary PBMC
taken from HFRS patients, and cells that were both cultured and infected in vitro in the lab. This was
done to analyze different components of the infection, both in the target cell type (endothelial cells)
isolated from the immune response and immune cells directly involved in the response. The cell lines
from the studies used in this investigation, human umbilical vein endothelial cells (HUVEC) and A549
(alveolar adenocarcinoma derived cells) are both commonly used models for infection and are a
representative model for identifying genes that are modulated as a direct response to infection, and not
due to any damage from the immune response. The primary cells are, on the other hand, not the primary
target of infection, although in more severe cases of HFRS, CD8+ T-cells, monocytes, and dendritic cells
may be potential targets for infection[58, 59]. The purpose of processing this data was to find underlying
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genes and pathways associated with the immune response to predict potential contributing factors to the
extreme “cytokine storm” response to hantavirus infection.
In the primary PBMC comparison, we found that of the top 10 differentially expressed genes,
only the NUSAP1 gene, which plays a role in microtubule organization [60], was upregulated. In contrast,
MYBL1 was the top hit, which is a protooncogene that is predicted to be associated with promoting
piRNA and PIWI expression, was found to be strongly downregulated[61]. PIWI-interacting RNA, or
piRNA, are small RNAs that play a role, along with PIWI proteins, in silencing mobile DNA elements in
the genome [62]. A recent study found that some PIWI pathways may be useful in antiviral defense
against viruses in insects, but nothing has been investigated in mammals, although these pathways have
been proposed to exist [63, 64].
As stated above, of the top 100 genes identified in primary PBMCs, only OLFM1, CCR7,
KLRG1, and PTGDR2 have been identified in previous hantavirus publications. OLFM1, which produces
olfactomedin and was found to be associated with hantavirus in a previous study, is also found to be
highly expressed in neuronal tissue and may aid in nervous system development; however, relatively little
is understood about many of its functions in other cell types [65]. Further, while it was identified as
downregulated in a prior study, we found it to be upregulated in our meta-analysis, but its potential role in
hantavirus has not been studied. Interestingly, while this gene is expressed in monocytes, its function is
unknown and warrants future investigation [66]. Additionally, three of the top 10 genes found in this
analysis, ZNF365, NOG and AMIGO1, regulate proper neuronal development[67-70]. Hantavirus rarely
affects the nervous system and has not been observed to directly infect nervous tissue, but these genes
may also play a role in the development of other cell types that can be affected during hantavirus infection
of PBMCs. While not fully understood, they may have a useful function when expressed in activated
PBMCs, or they may share common transcriptional activators with other genes that are activated during
hantavirus infection.
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CCR7, or C-C Motif Chemokine Receptor seven, is upregulated in lymphocytes and monocytes
during a variety of viral infections. A previous study showed that CCR7 induces monocyte egress during
hantavirus infection, and therefore a decrease in the number of CCR7-expressing monocytes occurs in the
bloodstream [55]. While this may account for the decrease in overall expression, it is unknown if
lymphocyte expression of this gene is modulated by hantavirus infection, as has been indicated by our
meta-analysis. Similarly, KLRG1, an NK cell receptor, is upregulated in T-cells generally during viral
infection, but previous studies have not indicated whether or not it is modulated by hantavirus
infection[56]. Our data indicates that it is downregulated during infection with hantavirus, which is novel,
especially when current research shows that NK cells actively proliferate during hantavirus infection[71].
Further investigation is needed to determine if hantaviruses can actively infect NK cells, which would be
a novel addendum to hantavirus research, or if the downregulation is due to signals from other cytokines.
PTGDR2, or the prostaglandin D2 receptor, promotes inflammation during a viral infection [72].
While no studies of this gene in association with hantavirus have been performed in humans, a 2014 study
found that deer mice, a natural non-symptomatic host for the virus, upregulate this gene during active
infection of Andes virus, a species of hantavirus [57]. Our analysis showed that this gene is strongly
downregulated in humans during infection of HTNV, another hantavirus. Although our observation could
be due to a difference in viral species or strain, the gene product may play a role in human pathogenesis
of the virus that is not seen in murine species, and likely warrants additional investigation, as it may
contribute to the excessive cytokine signaling seen in infected tissue.
The most significant upregulated genes primary PBMCs were NUSAP1, KIF20A, CDC25C, and
DEPDC1 and were associated with cellular division, especially in rapidly dividing cells, which is
expected during active viral infection and tissue repair [73-77]. In addition, CDC25C has been shown to
play a role in inhibiting viral replication of HSV, however there is no research indicating whether this is
true in other viruses such as hantavirus [78].

24

In vitro, of all the DEGs, only SLC27A3, AC090527.2 (a novel, uncharacterized gene not shown
on Figure 2-3), and TSEN34 were not associated with interferon stimulation and are not part of the
antiviral response. SLC27A3, which is a Very Long-Chain Acyl-CoA Synthetase, is both a synthetase and
a transport protein. It has a role in brain development but has not previously been associated with viral
pathogenesis or the immune response [79]. The tRNA Splicing Endonuclease 34 (TSEN34) gene, and
novel gene AC090527.2 similarly have no immune associated function. Finally, Immunoglobulin Heavy
Constant Gamma 2 (IGHG2), is shown to be strongly downregulated. This is unexpected since the
endothelial cells used in this analysis normally do not produce immunoglobulin. This may be a result of
the some of the cell lines being immortalized, or as an artifact of the analysis. However, at least one prior
study has shown that primary endothelial cells can produce antibodies in vitro [80].
The pathway analysis revealed a much wider variety of genes and perturbed pathways In the
primary PBMC dataset as compared to the in vitro dataset. We believe that one of the primary causes of
this difference is likely the higher content and complexity of cellular signals that are present in the
primary PBMC dataset. As the putative cause for the disease is a cytokine storm, we expected to see
cytokine signaling along with the interferon response in addition to repair pathways that would not be
seen in vitro [16]. Of interest in the in vitro enriched pathways are the inhibition of the RIG-I/MDA5
signaling pathways associated with viral detection. Although they were inhibited, the interferon pathway
downstream from them was still upregulated. This observations could mean another cellular pathway
inducing the interferon response, such as through TLR4 or IRF3, could play a role [81-83]. This is in
accordance with much of the current research, which shows that RIG-I is a part of the interferon response
in hantavirus infection and that glycoproteins from hantavirus can inhibit RIG-I activity, but there is
uncertainty on which pathways are essential to the activation of interferon stimulated genes (ISGs) during
a hantavirus infection. Our data indicates that while the RIG-I complex may certainly play a role during
infection, but it is not essential to the downstream activation of interferon.
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Using data from the pathway analysis, medications identified for the primary PBMC dataset
generally treat rapidly dividing and surviving cells, such as in cancer. Specifically, the drugs we predicted
would affect the highest number of primary PBMC pathways in this analysis included those that target
cyclin-dependent kinases and JAK kinases such as dinaciclib, alvocidib, and roniciclib. All three of these
therapeutics have shown promise as a host-based therapy that limits viral replication in other pathogens
[84-87], but none have been identified or tested for hantaviruses previously. Interestingly, our approach
ranked these drugs higher than other potential therapeutics on the list, which have previously been used as
host-based therapies that limit viral replication, such as vorinostat [88-90]. In contrast, the therapeutic
prediction analysis from the in vitro dataset identified baricitinib and interferon derivatives, which are
commonly used for viral infections [91-93]. As of now, there are no effective treatments for hantavirus
infection, and the current suggested remedy is supportive therapy such as bed rest and IV fluids [37]. We
believe that testing a subset of these drugs in a laboratory setting would be justified, and that laboratory
validation of these findings could improve treatment options for patients in the clinic.
The primary purpose of this study was to analyze the existing public RNA-seq datasets to
improve our understanding of the response of human cells during hantavirus infection and to predict
existing drugs that could be repurposed as host-based therapeutics. Specifically, we identified seven genes
that are novel to the human response to hantaviruses, as well as multiple signaling pathways and drugs
that could be repurposed as therapeutics. Such treatments could benefit patients by reducing the
occurrence of HFRS and HCPS. The results of this study remain speculative until they can be validated in
vitro, however we hope this will guide future research that is needed to understand how hantaviruses
impact gene expression in the human cell and to improve the identification, development, and testing of
effective treatments.
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CHAPTER 3
METAGENOMIC META-ANALYSIS FOR IDENTIFYING COMMONALITIES IN GUT BIOMES
BETWEEN CROHN’S DISEASE PATIENTS IN MULTIPLE POPULATIONS
The content from this chapter is currently being prepped for submission for publication
BACKGROUND
Crohn’s disease is becoming an increasingly prevalent health problem in developed nations. In
the United States alone, it is estimated that about 1 in 400 adults has CD, and that number is expected to
rise if current trends persist[20, 94]. This results in a roughly 10 billion dollar burden on the US economy,
and those with severe disease generating as much as 9 times more in medical costs as compared to those
in remission [95]. A recent study found that more than one in four Crohn’s disease patients were
dependent on steroids to manage their condition, and about half depend on thiopurine medications[96].
Both of these classes of medications have a well-documented history of use in the medical field, and the
potential dangers of their use are well known. They can be especially risky for developing children, but in
severe disease they may be necessary [97, 98]. Despite these advancements in diagnosis and treatment,
about one fourth of CD patients may be hospitalized each year [99].
The introduction of biologics, i.e. monoclonal antibody medications, has significantly reduced the
burden of disease [100, 101]. However, even with these advanced medications, identifying root causes of
initiation and progression of Crohn’s disease is a surer route to finding a cure. Environmental factors play
a large role in the development and diversity of the gut biome, and by extension the severity of CD
symptoms. Diet, water sourcing, radiation, and medicine—especially antibiotics—are a few among a
plethora of environmental sources that constantly impact the microbiome health of an individual. While
these factors may differ between communities, or even between people, we hope to look at a national
scale and compare CD patients in the United States. The western diet is oversaturated with fatty foods and
peoples of the United States rely heavily on medications and antibiotics. While these are generalizations,
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by analyzing large datasets we use these cultural, dietary, and other differences among these populations
to identify differences in gut diversity generally. Beyond this, we identified underlying similarities that
exist between CD patient populations in the US that we hope represent general patterns of CD patient
microbiomes.
To get a wide degree of sampling, shotgun metagenomic data from five projects across the United
States were reprocessed using the metaWRAP metagenomic pipeline. Each dataset was processed
separately to produce high quality bins. A bin represents a hypothetical genome assembly of a single
organism from within the sequenced microbial community, and individually contains the previously
generated contigs that have been sorted, or “binned” together. This binning process is informed by the
relative abundance of reads and contigs across all the submitted samples. A high-quality bin would be one
calculated to be over 70 percent complete with less than 5 percent contamination, which are the
standardized criteria that the ENA considers to be “real”. We then found the relative abundance of these
bins across all samples in the study to Identify patterns of bacterial presence both within populations and
bins associated with CD patents. In addition to finding and quantifying relative abundance, we classified
and annotated each bin. Some bins represent previously unidentified bacterial species and may require
isolation in a wet lab setting for more comprehensive fully identification and characterization.

RESULTS
Between all datasets, over 1000 high-quality bins were produced by the metaWRAP bin
refinement module. Although these bins aren’t specifically designed for colony composition studies, we
can get an idea of the composition by using the bin classification. The specificity of the classification,
potentially down to the strain, depends on the bin’s completion. With a standard of at least 70 percent,
most of the bins could be at least identified within a phylum, though many could be identified within a
family or genus.

28

Based solely on the bacterial phylogeny, the controls of the United States population are remarkably
similar to those with CD (Figure 3-1, Figure 3-2). Indeed, a phylogenetic-based approach to
understanding metagenomics is limited, but deeper inspection allows for more specific understanding of
potential underlying patterns, especially when compared to 16S amplicon-based sequencing. Five of the
bins that were exclusive to the Crohn’s set have been identified as Fusobacterium, of which two are
Fusobacteria ulcerans. The presence of these bacteria has been noted in cases of ulcerative colitis, which
is another irritable bowel syndrome (IBD) and is similar to CD, but it has only been weakly tied to
potentially playing a role in CD[102, 103]. We calculated percentages, rather than using raw numbers as a
normalization method since more bins were generated from the Crohn’s population. Overall, there were
many more samples used to create bins, so this observation was expected.
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Gut Bacterial Composition of CD Patients
in the United States
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Figure 3-1: Gut Bacterial Composition of CD Patients. Estimations are made based classification
output from taxator-tk of refined bins generated from samples collected across studies.

Gut Bacterial Composition of Control
Patients in the United States
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Figure 3-2: Gut Bacterial Composition of Controls. Estimations are made based classification output
from taxator-tk of refined bins generated from samples collected across studies.
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Next, we looked at the annotations generated by prokka (Figure 3-3). Using a custom script, we
retrieved all toxin related genes from the dataset and created an overall count of each toxin gene. Again,
due to having a larger dataset, more genes are present in the Crohn’s set, however when compared as a
percentage of total toxin genes identified, it appears that the control has more toxins present than Crohn’s
patients. This observation was rectified when we excluded the large number of less-common genes that
were only identified in the CD dataset.

Percentage of Toxin Genes Found

Top 15 Toxin Genes Found in Bins Generated
25.00%
20.00%
15.00%
10.00%
5.00%
0.00%
VgrG1 YezG HigA2 RelJ HigA1 DinJ HipB YefM HicB SocA HigA PezA HipA YafQ TabA

Toxins Identified
Control

Crohns

Figure 3-3: The Top 15 Bacterial Toxin Genes Found in Bins Generated by the Bin Refinement Module.
Percentage represents percentage of the number of a toxin gene found in comparison to all toxin genes
found within the bins of that condition (Crohn’s or Control). The differences were found not to be
statistically significant (p < 0.05).

DISCUSSION
Our analysis revealed several interesting patterns from this data. First, is that the bin diversity is
not indicative of disease status. Bins that reached over 70 percent completion were included, so more
uncommon bacterial strains in the gut were, the nature of the study, not included. Another reason for this
might be that diet is masking some of the underlying markers of the disease state. In concurrence with
current research, if the gut bacterial dysbiosis caused by western diet or environment is similar to one that
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is indicative, or even partially causative, of disease, this could explain prevalence in western
countries[27].
A recent study found that Actinobacteria, Fusobacteria, Firmicutes and Bacteroidetes are all
higher abundance in CD patients, but our data only showed an increase in Fusobacteria and
Bacteroidetes[104]. It was interesting to note the presence of Fusobacteria ulcerans, as while several
studies have analyzed the role of other Fusobacteria species in CD, F. ulcerans remains largely
uncharacterized in CD. There are several studies in current literature that indicate that Mycobacterium
avium subspecies paratuberculosis may be a causative agent of CD; however, it is a common pathogen
and most likely cannot explain all cases of CD [28, 105]. In addition, elimination of the pathogen does not
effectively reverse the effects of the disease completely in those that are affected [106]. However, this
does not exclude the possibility that multiple bacteria contribute to the induction and persistence of severe
disease [107, 108].
Additionally of note is that while CD progression is associated with bacterial toxin in serum,
these data indicate that the presence of any toxin gene alone is not indicative of disease state [109].
Instead, our data does not show any significant difference in the quantity or diversity of toxin genes
between the CD patients and the control. Either a meta-transcriptomic or a meta-proteomic analysis
would more definitively indicate if these genes have a change in expression. TabA, the most highly
present toxin, is associated with biofilm production and those with Crohn’s have a high amount of E. coli
generated biofilm in the gut and become particularly adherent and worsen disease symptoms
One of the weaknesses of our study is that it could not differentiate between active flaring CD
and CD in remission. The gut biome changes based on the activity of the disease, although it is uncertain
if the reverse is true, if the gut biome can independently induce remission or flare states[110]. However,
we wished to identify pathogens that were present in all CD patients regardless of disease state. Further,
we could not definitively quantify any particular gene from bins alone, but instead bins are more useful
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for understanding bin diversity and gene detection. However, using heat mapping of bin quantity per
sample could elucidate if particular bins are enriched in the samples.
In the process of this study, terabytes of data were produced. While we were interested in toxins,
any gene or series of genes could be investigated. An example of this would be biofilm production or
protein products that are well recognized PAMPs that perhaps increase inflammation. Further, several of
the generated bins have high predicted completion and low contamination percentages, but were unable to
be sorted into any phylum. This requires searching extensively through the genes and making
classification predictions based on predicted genes. This search is likely to identify previously
uncharacterized bacteria, whose role has not been studied in the context of gut health.
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CHAPTER 4
SNAKEWRAP: A SNAKEMAKE WORKFLOW TO FACILITATE AUTOMATED PROCESSING OF
METAGENOMIC DATA THROUGH THE METAWRAP PIPELINE
Taken from “SnakeWRAP: a Snakemake workflow to facilitate automated processing of metagenomic
data through the metaWRAP pipeline”
Manuscript in submission at F1000Research.

ABSTRACT
Generating high-quality genome assemblies of complex microbial populations from shotgun
metagenomics data is often a manually intensive task involving many computational steps. SnakeWRAP
is a novel tool, implemented in the Snakemake workflow language, to automate multiple metaWRAP
modules. Specifically, it wraps the shell scripts provided within the original metaWRAP software, within
Snakemake. This approach enables high-throughput simultaneous assembly and analysis of multiple
shotgun metagenomic datasets using the robust modular metaWRAP software. We expect this
advancement to be of import in institutions where high-performance computing infrastructure is available,
especially in the context of big data. This software tool is publicly available at
https://github.com/jkrapohl/SnakeWRAP

INTRODUCTION
As sequencing technology has become cheaper and more readily accessible, the need for the
increased computational capacity to process these data has become apparent. In particular, highthroughput sequencing has been particularly useful when applied to the field of metagenomics.
Substantial effort has been devoted to developing software and computational pipelines, such as
MetaWRAP, which cater to this growing area of research. MetaWRAP is a modular wrapper that
combines many of the necessary tools to process reads, create bins, and visualize data within a robust
modular design (Uritskiy, DiRuggiero, & Taylor, 2018). The primary limitation arising from this design
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is the inability to automatically scale its usage to massive datasets. However, its unique code that
produces exceptionally high quality bins from bins generated from other binning programs is invaluable.
Snakemake is a widely-used Python based workflow management system that automates repetitive tasks,
allowing software processes to be both scalable and reproducible (Mölder et al., 2021). By integrating the
original MetaWRAP processes into Snakemake, the customizable modular nature of MetaWRAP can be
preserved even when automatically processing large datasets through a single workflow. Our
SnakeWRAP software automates the tasks performed within MetaWRAP, allowing for individual
modules to be toggled on and off using Snakemake-defined rules.

METHODS
Implementation
As this tool makes use of Snakemake, individual steps of the workflow are broken into rules,
many of which can be toggled [111]. To do this, Snakemake requires a YAML configuration file as an
input to determine which steps are specified for the run, as well detailed parameters such as which
assembly tool to use. This configuration file also specifies the location of a metadata file, which contains
a list of files associated with the run. An example of both the YAML and metadata file are included in the
Github repository. SnakeWRAP can be submitted for scheduling from the command line by using the
submission script also found within the repository. Running the script requires the complete installation of
both Snakemake and METAWrap, as well as all of their dependencies. It is recommended that
Snakemake and METAWrap be installed using the latest version of Miniconda, following instructions
found on their corresponding Github repositories [43, 111].

Operation
The advantage of using SnakeWRAP over the base metaWRAP program is the ability to
appropriately support largescale job sizes while requiring less user input by automating the entire process.
This enables jobs to be better organized and allows improved consistency in outputs. We recommended
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that this tool be run on cluster computing or within a high-performance infrastructure for larger jobs. In
such cases, we have found that a minimum of 100 GB of RAM across 24 CPUs is sufficient, with larger
jobs requiring additional resources. The rules found within the Snakemake file correspond to different
steps within the original metaWRAP software. Some initial required steps include read quality control,
assembly, binning, and bin refinement and reassembly. However, we have provided toggle settings for
memory-heavy modules that generate figures, which are Blobology, Kraken, bin quantification, bin
annotation, and bin classification. This design reduces resource usage by only generating the desired
figures and allows the modification of this setting to create these figures at a later time by toggling the
module on in the YAML file, deleting any outputs created for that module, and resubmitting the job.
Snakemake will skip any rules already completed and only run the required rule(s).

Use Cases
As stated above, this tool works best with a high-performance computing infrastructure. We
anticipate that the most effective use of this tool is applying it to big metagenomics data, such as metaanalyses of existing datasets or datasets with many samples. To assess the capabilities of this tool, the
publicly available samples SRR13296364 and SRR13296365, accessed from the NCBI Sequence Read
Archive from the study SRP299130, were run together successfully. We then ran a larger set of files from
the SRP257563 study through the metaWRAP pipeline using this software. We found that this tool will
run as expected as long as sufficient memory is provided and all dependencies are installed correctly.
Inputs include sequencing files in fastq format, a metadata file listing all fastq filenames, and a YAML
file describing paths for all file sources and destinations. Outputs include high-quality genomic bins, as
wells as a number of generated figures such as a blobplot, heatmap, and kronogram.

DISCUSSION
While the processing of metagenomics datasets is untractable for most personal computers,
researchers with access to high-performance computing infrastructure can take full advantage of this
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software. The core functions found within the original MetaWRAP include read quality control,
assembly, and binning are required for the analysis and cannot be toggled off. These functions include
several refinement steps that are unique to MetaWRAP, which allow it to create higher-quality bins than
existing stand-alone programs [112]. Our design enables the user to decide whether computationallyexpensive modules, such as Kraken and Blobology, that assist with figure generation can be skipped.
Snakemake automatically generates a directed acyclic graph (DAG) to order tasks, track the progress of
each task for each sample, and eliminate duplicate tasks for the same sample [111]. This is vital to
efficiently processing and analyzing large datasets, as jobs can fail due to insufficient memory or timing
out. An advantage of implementing this workflow in Snakemake is the ability to resume the workflow
from the same step that was underway if a process fails. The input paths, output paths, and parameters for
each job are assigned by the end-user within a configuration file. This file is read by Snakemake to
prevent data from being incorrectly assigned or lost and to facilitate reuse and customization of the
workflow. We anticipate that this advance in automating data processing will facilitate the generation,
analysis, and re-analysis of larger datasets in the future.

37

CONCLUSION
In the microbiological and health fields of research, computation is becoming increasingly
essential. In this thesis two computational approaches are described, transcriptomics and metagenomics.
While they are but two of countless sequence-based tools that have been developed, they have practical
uses in the study of human health. Transcriptomics has allowed us to understand the human response to
stimuli of interest, in this case being hantavirus infection, and using that to identify potential routes of
research. In this study, we identified genes, pathways, and drugs that have the potential to treat infection,
and would be worth investigating. With these data, future studies can narrow their focus on specific
interactions when developing novel treatments and investigating underlying mechanisms of Hantavirus
infection.
Outbreaks of hantavirus infection are sporadic, but can be incredibly dangerous, with death tolls
of over 100,000 people per year [113]. Several vaccines are under investigation, but none of them has
seen great efficacy or range of viral species in part due to the difficulty to have widespread vaccinations
in impoverished areas. [10, 37]. Despite this, hantavirus remains a lower priority due to its inability to be
transmitted between human hosts. However, with the recent Covid-19 pandemic, the threat of a novel
zoonotic virus is now regarded as much more of a threat. Certainly, Orthohantavirus is well-established
in rodent populations around the world and will likely continue to be a threat to human health. By using
and building upon identified potential therapeutics, we can lower current mortality rates and be prepared
in the event of an outbreak or epidemic.
The gut microbiome has been described as the “hidden organ” and remains neglected as a
component of human health due to the difficulty in understanding its function and role in disease.
Metagenomics allows us to approach gut microbial biomes and identify patterns that exist within the
community. In particular, shotgun metagenomics, or whole genome metagenomics, has only become
possible due to recent advances in computational power. Because of this, a rich new layer of
understanding can be extracted from metagenomics sequencing without any need for bacterial isolation or
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16S amplification. While we identified bacterial abundance and the presence of harmful bacterial genes,
any community could be studied and lead to the discovery of new genes and species. Through our work,
we have generated terabytes of data to analyze. We could build upon this further by including more
control datasets, or by including other gut disorders in the analysis, such as ulcerative colitis or colon
cancer. Such an approach could provide interesting comparisons and contrasts between gut disorders.
Future work can better characterize the bacterial role in disease, which can then be translated into the
development of new treatments, and medication that can be better tailored to the individual.
Overall, we believe that our findings improve our mechanistic understanding of these diseases
and may contribute to the future development, testing, and availability of novel treatments to improve
human health.
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FUTURE DIRECTIONS
In my time as a Master’s student, I found time to be the most limiting factor to my research, as
only so much can be done over the course of two years. There are several components of my research that
could be expanded upon and further developed if given the time. Within the hantavirus project, I would
test to see if any of the predicted drugs had the potential of limiting infection and replication of hantavirus
within cell culture, and if successful, collaborate with another university to test that drug within a hamster
model. Next, I would test to see how hantavirus transcriptional modulation occurs within different
cultured primary cells. We could compare RNA isolated from primary lung tissue, kidney tissue, cardiac
tissue, and even blood cells during an in vitro infection. By performing RNA-seq we could potentially
predict which genes and pathways contribute to a symptomatic or asymptomatic phenotype during
hantavirus infection and the potential for more targeted treatments.
If I were to continue with the Crohn’s disease project, there are several avenues I would like to
explore. First, I would expand my datasets to include as many countries as possible as part of the analysis
to identify commonalities between Crohn’s disease patients on a more global scale. In addition, I would
want to do a more comprehensive review of F. ulcerans as well as do a comparison of our assembled bins
against the NCBI reference genome to see if there are genes of interest that are present only in the
assembled bins. Finally, there are several bins that were well-assembled with little contamination but
were not classified. They most likely represent novel strains of bacteria and would be of interest in future
gut microbiome projects moving forward. More importantly, they could be undiscovered contributing
factors in Crohn’s disease that have yet to be isolated and cultured. To identify them, we would have to
through the genome and manually identify genes using BLAST (Basic Local Alignment Search Tool)
[114]. Additionally, we could use a common or universal bacterial gene, such as a sigma factor or 16S
sequence to place the bins within a tree alongside reference genomes to see how similar they are to known
bacteria. In this same way, other genes, besides toxins, could be analyzed in relation to Crohn’s disease.
There are still several potential ways to expand these projects, whether in silico or in vitro.
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The following is a copy of “Preprocessing of Public RNA-Sequencing Datasets to Facilitate Downstream
Analyses of Human Diseases”, of which I was a contributing, but not primary author. The citation for this
article is:
Rapier-Sharman N, Krapohl J, Beausoleil EJ, Gifford KTL, Hinatsu BR, Hoffmann CS, Komer M, Scott
TM, Pickett BE. Preprocessing of Public RNA-Sequencing Datasets to Facilitate Downstream Analyses
of Human Diseases. Data. 2021; 6(7):75. https://doi.org/10.3390/data6070075
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